Challenges for imaging angiogenesis

British Journal of Radiology

Volumn 74, Issue 886, 2001, Pages 886-890

  Padhani, A R ^a   Neeman, M ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BLOOD VESSEL PARAMETERS; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IMAGING SYSTEM; LONG TERM CARE; NONHUMAN; REVIEW; TUMOR VASCULARIZATION;

EID: 0035163875     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.74.886.740886     Document Type: Review

References (33)

1. Molecular mechanisms of blood vessel growth
2. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: Implications for angiogenesis
3. Initial stages of tumour cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
4. New perspectives in clinical oncology from angiogenesis research
5. Consequences of angiogenesis for tumour progression, metastasis and cancer therapy
6. Immunophenotype of intraductal carcinoma
7. Ductal carcinoma in situ: MR imaging-histopathologic correlation
8. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis
9. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
10. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
11. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
12. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow
13. Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF)
14. Therapeutic angiogenesis
15. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
16. Regression of metastatic breast cancer in a patient with the anti-angiogenic drug TNP-470
17. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
18. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
19. Redefining the target: Chemotherapeutics as antiangiogenics
20. Application of CT in the investigation of angiogenesis in oncology
21. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: A review
22. Evaluation of tumour angiogenesis with US: Imaging, Doppler, and contrast agents
23. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma
24. In vivo monitoring of tumour angiogenesis with MR imaging
25. Mammary carcinoma model: Correlation of macromolecular contrast-enhanced MR imaging characterizations of tumour microvasculature and histologic capillary density
26. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
27. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: Magnetic resonance imaging of C6 rat glioma in nude mice
28. Role of radionuclide imaging in trials of antiangiogenic therapy
29. Detection of tumour angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
30. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
31. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin
32. In vivo detection and imaging of phosphatidylserine expression during programmed cell death
33. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumour therapies